Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by AGC Biologics

AGC Biologics Forms Dedicated “Cell and Gene Technologies Division,” Designed to Build Upon Their Track Record of Nine Commercially Approved Products to Date
From AGC Biologics
Via Business Wire
AGC Biologics Honored by Customers and Industry Leaders for Excellence in Contract Development and Manufacturing
From AGC Biologics
Via Business Wire
AGC Biologics Milan Receives Special Award Mention by Confindustria for Research and Innovation
From AGC Biologics
Via Business Wire
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product
From AGC Biologics
Via Business Wire
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg
From AGC Biologics
Via Business Wire
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months
From AGC Biologics
Via Business Wire
AGC Biologics Expands Cell Therapy Suites at Longmont ATMP Campus
From AGC Biologics
Via Business Wire
AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project
From AGC Biologics
Via Business Wire
AGC Biologics Completes Expansion at Milan Cell and Gene Therapy Development and Manufacturing Site
From AGC Biologics
Via Business Wire
AGC Biologics Introduces AGCellerate, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity
From AGC Biologics
Via Business Wire
AGC Biologics Launches BravoAAV™ and ProntoLVV™ Platforms offering Flexible and Accelerated Vector Development and Manufacturing for Cell and Gene Therapy Programs
From AGC Biologics
Via Business Wire
AGC Biologics Received Bioprocessing Excellence Award in Japan
From AGC Biologics
Via Business Wire
AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project
From AGC Biologics
Via Business Wire
AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™
From AGC Biologics
Via Business Wire
AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
From AGC Biologics
Via GlobeNewswire
AGC Biologics Honored for Innovations in Cell Line Development
From AGC Biologics
Via GlobeNewswire
AGC Biologics Supports Altheia Science’s Gene Therapy Programs
From AGC Biologics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.